BioLight Life Sciences Investments Ltd. (OTC: BLGTY, TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops.
BioLight will co-manage the new company and will hold 40% equity stake.This drug-delivery platform will help address improve patient compliance with eye disease drug regimens and will form the basis for possible drug development by the new company targeting diseases affecting both the front and back of the eye.
Suzana Nahum-Zilberberg, BioLight's chief executive officer, said, "This new investment represents a major step in our goal to expand our ophthalmic portfolio that addresses clear unmet needs in the multibillion dollar ophthalmic drug market. Our experience in the ophthalmic space will definitely contribute to the new company efforts to find the best ways to develop this novel drug delivery technology into a portfolio of new drugs with better efficacy and safety profiles."